Nicola Dagg is a partner in the IP litigation team in the London office of Kirkland & Ellis International LLP. Nicola’s practice spans four areas:
►(1) strategic life sciences patent and product lifecycle advice;
►(2) patent litigation;
►(3) co-ordinating global IP enforcement/defence cases; and
►(4) standard essential patent (SEP) and FRAND disputes. Nicola has tried over 20 cases.
Nicola has extensive experience in pharmaceutical and biologics patent litigation including blockbuster small molecule litigation against generic companies, biologics and biosimilar litigation, antibodies, immunotherapies, genetics, vaccines, diagnostics and gene therapies. Nicola also acts in market leading SEP essentiality, validity and global FRAND adjudication litigation in the tech sector. Having served as UK and European/global coordinating counsel for numerous strategic IP litigation cases and drawing on more than 24 years of legal, IP, life sciences and tech experience she helps clients solve their most pressing global challenges.
Nicola writes and speaks extensively on intellectual property litigation. Chambers Global 2020 recognises Nicola as a “pre-eminent” litigator who is “fantastic – extremely strategic, laser-focused and gets the right results for her clients”. In their 2019 directory IAM Patent 1000 describe her as “fantastic – the driving force in what is one of the great success stories in recent years” and acknowledge her “impressive” team-building and client-handling skills.
Kirkland & Ellis International LLP
EC3A 8AF London
United Kingdom
+44 20 7469 2150
nicola.dagg@kirkland.com